FDA has granted approval to NEPHRON for the brand name drug referenced in ANDA215268, a regulatory milestone that solidifies the company's position in the market. Although the specific substance remains undisclosed, the approval signals strong commercial potential and positions NEPHRON to capture a significant market share.